Fuda Cancer Hospital

Fuda Cancer Hospital (officially Fuda Cancer Hospital of Jinan University) is an internationally recognized cancer treatment center located in Guangzhou, Guangdong Province, China. Affiliated with Jinan University, the hospital has gained worldwide acclaim as a pioneer in minimally invasive cancer therapies, particularly cryosurgery (cryoablation) and irreversible electroporation (NanoKnife technology). Founded in 2003 under the leadership of Professor Xu Kecheng, the hospital has treated over 30,000 cancer patients from more than 80 countries. The hospital operates with approximately 300 beds across two campuses in Guangzhou, with dedicated international patient wards featuring multilingual staff and culturally sensitive care. The hospital's signature treatment is percutaneous cryoablation (cryosurgery), where tumors are destroyed by freezing them to extremely low temperatures (-196°C using liquid nitrogen or argon-helium). Fuda has performed more cryosurgery procedures than any other hospital globally and has published extensively on the technique's efficacy for liver, lung, pancreatic, kidney, and breast cancers. The NanoKnife (Irreversible Electroporation) program uses high-voltage electrical pulses to destroy cancer cells while preserving surrounding blood vessels and bile ducts, making it particularly effective for pancreatic cancer and tumors near critical structures. Combined with brachytherapy (iodine-125 seed implantation), photodynamic therapy, and immunotherapy protocols including dendritic cell vaccines and CAR-T cell therapy, Fuda offers one of the most comprehensive arsenals of minimally invasive oncology treatments in Asia. The hospital also provides conventional cancer treatments including chemotherapy, targeted therapy, and traditional Chinese medicine-based supportive care. Research partnerships with institutions in the United States, Japan, Australia, and Europe ensure continuous innovation. Fuda is JCI-accredited and holds ISO 9001 certification.